Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins Eloxatin patent case

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin (oxaliplatin) until August 2012 following a patent challenge from Sun Pharmaceuticals.

Sun Pharma was appealing a district court ruling from April 2010 requiring Sun to cease selling its generic oxaliplatin products as of June 30, 2010.

Sanofi had previously reached settlement agreements with several other pharmaceutical companies, including Teva Pharmaceutical and Sandoz, prohibiting the sale of generic Eloxatin products in the US until August, 2012.

In recently released financial results, Sanofi reported the drug had sales €436m for Sanofi during the first half of 2011.

The company said it still sees Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics